Securing Infrastructure for Human Tissue Processing
Expansion into CDMO and Regenerative Medicine Businesses

SijiMedTec, a company specializing in research and manufacturing of orthopedic and dental implants, announced on April 10 that it has acquired the Seongnam Human Tissue Processing Bank owned by SijiBio, and will officially begin expanding its human tissue-based bio business.


Through this acquisition, SijiMedTec has secured a human tissue processing facility with a history of AATB certification and compliance with FDA regulations, along with all key equipment. In addition, the company has integrated a cell processing facility, establishing a production infrastructure that meets global standards. This move is expected to provide both a stable production system for human tissue processing and a foundation for mid- to long-term expansion.

Exterior view of the Seegimedtec Seongnam Human Tissue Bank. Seegimedtec

Exterior view of the Seegimedtec Seongnam Human Tissue Bank. Seegimedtec

View original image

With this acquisition, SijiMedTec plans to actively pursue ECM (Extracellular Matrix)-based therapeutics and regenerative skin booster businesses. ECM, a biomaterial that induces tissue regeneration, is considered a next-generation bio material with high potential for use in a variety of medical fields, such as skin, soft tissue, and bone tissue regeneration.


Furthermore, integration with the existing dental business will be strengthened. SijiMedTec plans to produce bone graft materials for alveolar bone as part of its dental portfolio expansion, and aims to further enhance synergies between its implant business and bio-material business.


This acquisition is seen as a turning point for SijiMedTec, expanding its business portfolio beyond its existing focus on spine and orthopedics to include dental and broader bio sectors. In particular, by directly securing production infrastructure, the company expects to be able to respond more organically across the development, production, and commercialization of related products in the future.



Hyunseung Yoo, CEO of SijiMedTec, said, "This acquisition is an important milestone for SijiMedTec, as it allows us to secure a foundation for human tissue processing and expand into the bio sector. We will continue to broaden our portfolio with ECM-based therapeutics, regenerative skin boosters, and bone graft materials for alveolar bone, while also strengthening our CDMO business capabilities based on synergies with our spine, orthopedic, and dental businesses."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing